Centene Corporation Sued for Securities Fraud

Strategic Insights -

Centene Corporation, a leading healthcare company, is facing a lawsuit filed by a securities law firm on behalf of investors who purchased the company's securities. The lawsuit alleges that the company and its senior executives violated federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The case is pending in the U.S. District Court for the Southern District of New York, captioned Lunstrum v. Centene Corporation, et al., No. 25-cv-05659.

The lawsuit centers around Centene's financial guidance for fiscal year 2025, which the company initially stated would reflect "[s]tability in earnings power in the face of unprecedented headwinds." However, the company later increased its guidance due to enrollment "overperformance" and touting the "progress we are making as an organization while navigating a dynamic policy landscape." In reality, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates.

Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group, which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. This led to a significant decline in the price of Centene stock, falling $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.

Key Takeaways:

  • Centene Corporation is facing a lawsuit filed by a securities law firm on behalf of investors who purchased the company's securities.
  • The lawsuit alleges that the company and its senior executives violated federal securities laws.
  • Centene's financial guidance for fiscal year 2025 was initially stated to reflect "stability in earnings power in the face of unprecedented headwinds."
  • The company later increased its guidance due to enrollment "overperformance" and touting the "progress we are making as an organization while navigating a dynamic policy landscape."
  • An independent actuarial report from Wakely Consulting Group showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected.
  • The price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • The case is pending in the U.S. District Court for the Southern District of New York, captioned Lunstrum v. Centene Corporation, et al., No. 25-cv-05659.
  • The lawsuit is being led by Bleichmar Fonti & Auld LLP, a leading international law firm representing plaintiffs in securities class actions and shareholder litigation.
  • The firm has recovered over $900 million in value from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Statistics:

  • Centene stock price fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • The case is pending in the U.S. District Court for the Southern District of New York, captioned Lunstrum v. Centene Corporation, et al., No. 25-cv-05659.
  • The lawsuit is being led by Bleichmar Fonti & Auld LLP, a leading international law firm representing plaintiffs in securities class actions and shareholder litigation.

Sources:

  • GlobeNewswire, July 18, 2025
  • Centene Corporation, December 12, 2024
  • Centene Corporation, February 4, 2025
  • Centene Corporation, April 25, 2025
  • Wakely Consulting Group, (no date provided)
  • Bleichmar Fonti & Auld LLP, (no date provided)